The use of exenatide in severely burned pediatric patients.
about
Burns: an update on current pharmacotherapyClinical review: Glucose control in severely burned patients - current best practice.The potential role of incretin therapy in the hospital setting.Bench-to-bedside review: the gut as an endocrine organ in the critically illThe therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically illExogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatmentBurns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?Glucose metabolism in critically ill patients: are incretins an important player?Glucose control in non-critically ill inpatients with diabetes: towards closed-loop.Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.Nutrition and anabolic pharmacotherapies in the care of burn patients.Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.The metabolic stress response to burn trauma: current understanding and therapies.Glycemic variability: Clinical implications.Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.
P2860
Q24618730-A0188BD9-9294-4EFE-B534-F84720E5812EQ33750033-016B54F7-442C-4368-B129-D43B3BE933C1Q33792390-C43A1708-5DC6-41F3-9CC2-8BB8B2009665Q35559137-00862418-29A4-455A-8391-6B318A43B4E4Q35559222-22BE5EB8-B317-48AF-8AA8-EDFD54FA7571Q35567284-97CAFFF1-7500-4567-87E3-1C6B2B2488DFQ36942108-8F03DF4A-E680-49B1-83F9-196F7ADC1264Q37820839-90DC4D63-4753-464B-B448-8C87F9F1EC63Q38142955-58E197D3-5FF2-427A-9176-BFD998133230Q38165285-0D1F46EC-0C4A-4C7B-B783-31AE2AB0E805Q38303079-97CCE6DA-1A68-4F56-9ADC-F0381B392C9FQ38326632-B09B040B-6BF5-41B3-9EFD-F3E8651F919CQ38683079-550F579F-BD79-444A-8045-D1CC1AA41E7BQ38972966-5BFAE852-B66C-4357-9218-B5097043F8E3Q39364360-3094D576-511D-40EF-9418-0774BB8DB193Q41886708-3B1E91AC-C7E8-45E2-A5A1-7FFFBEDCDB7BQ54948267-47390689-7BBC-4937-ABAB-FC04C0C413F1
P2860
The use of exenatide in severely burned pediatric patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The use of exenatide in severely burned pediatric patients.
@ast
The use of exenatide in severely burned pediatric patients.
@en
The use of exenatide in severely burned pediatric patients.
@nl
type
label
The use of exenatide in severely burned pediatric patients.
@ast
The use of exenatide in severely burned pediatric patients.
@en
The use of exenatide in severely burned pediatric patients.
@nl
prefLabel
The use of exenatide in severely burned pediatric patients.
@ast
The use of exenatide in severely burned pediatric patients.
@en
The use of exenatide in severely burned pediatric patients.
@nl
P2093
P2860
P356
P1433
P1476
The use of exenatide in severely burned pediatric patients.
@en
P2093
Ahmed M Al-Mousawi
David N Herndon
Felicia N Williams
Gabriel A Mecott
Gabriela A Kulp
Haidy G Rivero
Ludwik K Branski
Marc G Jeschke
Natasha C Brooks
Robert Kraft
P2860
P2888
P356
10.1186/CC9222
P577
2010-08-11T00:00:00Z
P5875
P6179
1053662740